Therapeutic Insights
Filter News
Found 1,008 articles
-
Alzheimer's Helpline Expanding Hours to Provide Greater Support to Individuals and Family Members Starting This Saturday
7/9/2020
The Alzheimer's Foundation of America (AFA) is expanding the hours of its Helpline starting this Saturday, July 11 th . The new hours will be 9 am to 9 pm (ET) on weekdays and 9:00 am to 5:00 pm (ET) on weekends.
-
The submission was completed with ongoing collaboration with the FDA and include data from the Phase III EMERGE and ENGAGE trials, as well as the Phase Ib PRIME study. Biogen has also requested Priority Review.
-
The Alzheimer's Drug Discovery Foundation and Harrington Discovery Institute to Support Promising Research with Potential to Delay Onset or Slow Progression of Alzheimer's Disease
7/8/2020
The Alzheimer's Drug Discovery Foundation (ADDF) and Harrington Discovery Institute at University Hospitals have granted Eugenia Trushina , Ph.D., of Mayo Clinic Rochester, the ADDF-Harrington Sch
-
Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimer’s Disease
7/8/2020
If approved, aducanumab would be the first treatment with the potential to meaningfully change the course of Alzheimer’s disease
-
Novocure Enrolls Last Patient in HEPANOVA Trial Testing Tumor Treating Fields in Combination with Sorafenib in Advanced Liver Cancer
7/7/2020
Novocure (NASDAQ: NVCR) today announced that the last patient has been enrolled in the HEPANOVA trial, a phase 2 pilot trial testing Tumor Treating Fields in combination with sorafenib in patients with advanced liver cancer. The final data collection date is six months after the last patient in. “Tumor Treating Fields therapy has demonstrated efficacy in in vitr
-
AllerGenis Begins Testing Patient Samples for Peanut Allergy Using Proprietary Epitope Mapping Technology
6/24/2020
AllerGenis LLC, a data-driven precision diagnostics company focused on food allergies, today announced the onset of operations at its Hatfield facility to test patient samples using its VeriMAP TM Peanut Diagnostic, a diagnostic solution for patients with peanut allergies. AllerGenis received full certification under Clinical Laboratory Improvement Amendments of 1988 (CLIA) to perform its high complexity clinical l
-
Enzo Announces Issuance of U.S. Patent for Methods of Treating Liver Cancer Using Proprietary Compound SK1-I
6/23/2020
Enzo Biochem, Inc. (NYSE: ENZ), a leading biosciences and diagnostics company, today announced it has received a patent for the treatment of liver cancer, U.S. Patent No. 10,675,255 entitled Sphingosine Pathway Modulating Compounds for the Treatment of Cancers . Enzo’s patent is directed to methods for treating hepatocellular carcinoma (HCC), the
-
Median Technologies: iBiopsy®: Promising Results on a Preliminary Study to Evaluate the Risk of Tumor Recurrence in Patients With Primary Liver Cancer
6/17/2020
Encouraging preliminary results about the iBiopsy® clinical development plan on liver cancer and the technological methods therein Development of a fibrosis biomarker from CT scan imaging A better performing biomarker compared to existing imaging biomarkers
-
Cyclo Therapeutics Reports on Eighteen Month Expanded Access Program in Single Alzheimer’s Patient
6/17/2020
Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease, today announced that the final report on “Expanded Access to Trappsol ® Cyclo™ for an Individual Patient with late onset Alzheimer’s disease” has been rec
-
Amylyx Pharmaceuticals Announces Completion of Enrollment in the PEGASUS Trial of AMX0035 in Alzheimer’s Disease
6/15/2020
Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and other neurodegenerative diseases, today announced it has completed enrollment in the Phase II PEGASUS trial assessing AMX0035 in individuals with Alzheimer’s disease. Amylyx completed
-
Devonian Health Group Announces Notice of Allowance for a US Patent Application Covering Use of Thykamine™ for the Treatment of Ulcerative Colitis
6/15/2020
Devonian Health Group Inc. (“ Devonian ” or the “ Corporation ”) (TSXv:GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. patent application No. 15/772,155, titled, "Thylakoid Extract Composition and Form
-
Biopharmaceutical companies need to look beyond the usual targets when addressing neurodegenerative disorders and also must work to correlate genetic changes to cognitive changes in patients, according to panelists at BIO’s on-demand session, “Battle of the Brains: Rethinking Neurodegenerative Di...
-
After Disappointing Study Results, Denali and Sanofi Shift Resources to a Different Alzheimer's Drug
6/10/2020
Denali Therapeutics and its development partner Sanofi announced data from its Phase Ib trial of DNL747 in Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). -
New Two-Year PALFORZIA™ Data Show On-going Safety and Efficacy and Continued Immunomodulation in Patients with Peanut Allergy
6/8/2020
New Two-Year PALFORZIA™ Data Show On-going Safety and Efficacy and Continued Immunomodulation in Patients with Peanut Allergy — After Two Years of Daily Treatment, More Than 80% of Patients Were Successfully Desensitized to 2000 mg Peanut Protein or Equivalent of About 14 Peanut Kernels— — Majority of Patients Treated Daily Also Reported Lower Rates of Adverse Events and Showed Higher Rates of Desensitization Compared to Non-Daily Dosing Groups —
-
Cognition Therapeutics Receives $75.8 Million NIA Grant for 540-Patient Phase 2 Study of CT1812 in Collaboration with the Alzheimer's Clinical Trials Consortium
6/8/2020
Cognition Therapeutics, Inc. , a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease and other neurodegenerative disorders, today announced that the National Institute on Aging (NIA) of the National Institutes of Health (NIH) has awarded the Company a grant (number R01AG065248) expected to total $75.8 million over five years to support a 540-patient Phase 2 study of CT1812 in indi
-
AmorChem Invests in a Potential Treatment for Cerebral Amyloid Angiopathy and Alzheimer’s Disease
6/4/2020
AmorChem is proud to announce a new investment in a research program hailing from Université Laval and the Research Center of the Centre Hospitalier Universitaire de Québec. The venture capital fund identified the opportunity in close collaboration with SOVAR, a group active in the promotion of university research. Am
-
Tecentriq is an anti-PD-L1 checkpoint inhibitor. Avastin binds to the VEGF protein, which plays a significant role in the development and maintenance of blood vessels by cancer cells.
-
The Phase II study will be performed in collaboration with the National Institutes of Health under a $2.7 million grant.
-
Cyclo Therapeutics Inc. Announces Positive Top Line Results from Phase I Trial and Interim Analysis of Phase I/II Trial using Trappsol® Cyclo™ Intravenously to Treat Patients with Niemann-Pick Disease Type C1 (NPC1)
5/20/2020
Cyclo Therapeutics Inc. Announces Positive Top Line Results from Phase I Trial and Interim Analysis of Phase I/II Trial using Trappsol ® Cyclo™ Intravenously to Treat Patients with Niemann-Pick Disease Type C1 (NPC1) Top line results of Phase I study confirm favorable safety and tolerability of Trappsol ® Cyclo™ in patients with NPC1 and demonstrate biological responses for both dose groups. An Unblinded Interim Analysis of Phase I/II study shows encourag
-
Results of GERAS-US Study Demonstrate Societal Cost Burden for Patients and Caregivers During Early Stages of Alzheimer's Disease
5/19/2020
Early Alzheimer's disease poses financial burdens on patients, caregivers and society